OTCMKTS:PNEXF Pharnext (PNEXF) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free PNEXF Stock Alerts $400.00 0.00 (0.00%) (As of 07/13/2023) Add Compare Share Share Today's Range$400.00▼$400.0050-Day Range$400.00▼$4,000,000.0052-Week Range$0.0001▼$0.0010Volume16,660 shsAverage Volume433 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Pharnext alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Pharnext Stock (OTCMKTS:PNEXF)Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.Read More PNEXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PNEXF Stock News HeadlinesMarch 11, 2024 | finanznachrichten.dePHARNEXT: Pharnext takes full stock of its operating, strategic and financial situationFebruary 28, 2024 | actusnews.comPharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1AApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? February 25, 2024 | benzinga.comPHARNEXT by Pharnext Stock (OTC:PNEXF), Insider Trading ActivityJanuary 17, 2024 | finanznachrichten.dePHARNEXT: Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1AJanuary 17, 2024 | actusnews.comPharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1ADecember 15, 2023 | investing.comPharnext set to release pivotal trial data for CMT1A treatment PXT3003December 2, 2023 | morningstar.comPharnext SA ALPHAApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? November 20, 2023 | finanznachrichten.dePHARNEXT: Pharnext announces successful manufacturing of registration batches of PXT3003 in the United StatesNovember 20, 2023 | actusnews.comPharnext announces successful manufacturing of registration batches of PXT3003 in the United StatesOctober 16, 2023 | actusnews.comPharnext received two offers valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR 250m, and raises EUR 2.5mSeptember 28, 2023 | actusnews.comPharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A)July 10, 2023 | finanznachrichten.dePHARNEXT: Pharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory BoardJuly 10, 2023 | actusnews.comPharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory BoardJune 15, 2023 | actusnews.comPharnext appoints Gilbert Wagener, M.D., Ph.D. as Chief Medical OfficerJune 8, 2023 | actusnews.comPharnext supports and participates in the First European Charcot-Marie-Tooth disease Specialists ConferenceMay 22, 2023 | finanznachrichten.dePHARNEXT: Edison Investment Research publishes updates research report on PharnextMay 12, 2023 | finanznachrichten.dePHARNEXT: Pharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)May 12, 2023 | actusnews.comPharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)May 5, 2023 | finance.yahoo.comGlobal Dental Partnering 2010-2023: Deal Trends, Players and FinancialsApril 18, 2023 | actusnews.comPharnext supports the online 2023 Conference of CMTUK, the UK's Charity dedicated to supporting people living with Charcot-Marie-Tooth diseaseMarch 20, 2023 | finanznachrichten.dePHARNEXT: Pharnext supports and participates in two congresses on Neuromuscular Disorders in EuropeMarch 20, 2023 | actusnews.comPharnext supports and participates in two congresses on Neuromuscular Disorders in EuropeMarch 14, 2023 | actusnews.comPharnext supports and participates in two congresses dedicated to Charcot-Marie-Tooth diseases in Marseille, FranceMarch 6, 2023 | finanznachrichten.dePHARNEXT: Pharnext supports and participates in the 27th edition of the Francophone Peripheral Nerve Society conference (SFNP) in ParisFebruary 15, 2023 | finance.yahoo.comPharnext SA (ALPHA.PA)See More Headlines Receive PNEXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharnext and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:PNEXF CUSIPN/A CIKN/A Webwww.pharnext.com Phone(314) 109-2230FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Daniel E. Cohen (Age 70)Director Comp: $343.16kMr. Hugo Brugiere M.Sc.CEO & ChairmanMr. Ilya Chumakov Ph.D.D-Sc, Co-Founder, Chairman of Scientific Advisory Board and DirectorMr. Xavier Paoli M.Sc.Chief Operating OfficerMr. Vincent Serra Ph.D. (Age 53)COO & Chief Scientific Officer Mr. Abhijit PanguHead of Regulatory AffairsMr. Raj Thota M.Sc.Chief Manufacturing Officer & Head of CMCMr. Scott Johnson B.Sc.VP & Head of QualityMr. Gilbert Wagener M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors PNEXF Stock Analysis - Frequently Asked Questions How have PNEXF shares performed in 2024? Pharnext's stock was trading at $4,000,000.00 on January 1st, 2024. Since then, PNEXF stock has decreased by 100.0% and is now trading at $400.00. View the best growth stocks for 2024 here. When did Pharnext's stock split? Pharnext shares reverse split on the morning of Thursday, February 15th 2024. The 1-10000 reverse split was announced on Thursday, February 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Pharnext? Shares of PNEXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PNEXF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharnext SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
